AI Article Synopsis

Article Abstract

The mechanism of action of adrenaline on cardiac contractility in rat papillary muscles containing V1 and V3 isomyosins was analyzed during barium-activated contractures at 25 degrees C by frequency domain analysis using pseudo-random binary noise-modulated perturbations. The analysis characterizes a frequency (fmin) at which dynamic stiffness of a muscle is a minimum, a parameter that reflects the rate of cycling of crossbridges. We have previously shown that fmin for V1- and V3-containing papillary muscles were 2.1 +/- 0.2 Hz (mean +/- SD) (n = 10) and 1.1 +/- 0.2 Hz (n = 8), respectively, and that these values were independent of the level of activation. The present study's goal was to determine whether the inotropic action of adrenaline was associated with an increased rate of crossbridge cycling. The results show that a saturating dose of adrenaline increased fmin in V1 hearts by 49 +/- 2% (n = 11). The action on V3 hearts was significantly less; the increase in fmin was 26 +/- 2% (n = 6). The increase in fmin for V1 hearts was shown to be sensitive to the beta-blocking agent propranolol. These results suggest that adrenaline significantly increases the rate of crossbridge cycling by a beta-receptor-mediated mechanism. We conclude that the increased contractility of the heart in the presence of adrenaline arises not only from more complete activation of the contractile proteins but also from the increased rate at which each crossbridge can transduce energy.

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.res.62.3.452DOI Listing

Publication Analysis

Top Keywords

rate crossbridge
12
adrenaline increases
8
increases rate
8
rate cycling
8
cycling crossbridges
8
pseudo-random binary
8
binary noise-modulated
8
action adrenaline
8
papillary muscles
8
+/- +/-
8

Similar Publications

The cardiac myosin binding protein-C (cMyBP-C) regulates cross-bridge formation and controls the duration of systole and diastole at the whole heart level. As known, mutations in cMyBP-C increase the cross-bridge number and rate of their cycling, hypercontractility, and myocardial hypertrophy. We investigated the effects of the mutations D75N and P161S of cMyBP-C related to hypertrophic cardiomyopathy on the mechanism of force generation in isolated slow skeletal muscle fibers.

View Article and Find Full Text PDF

The force-length relationship is usually obtained for isometric contractions with maximal activation, but less is known about how sarcomere length affects force during submaximal activation. During submaximal activation, length-dependent alterations in calcium sensitivity, owing to changes in cross-bridge kinetics (rate of attachment and/or detachment), result in an activation-dependent shift in optimal length to longer sarcomere lengths. It is known that sarcomere length, as well as temperature and phosphorylation of the regulatory light chains of myosin, can modify Ca⁺ sensitivity by altering the probability of cross-bridge interaction.

View Article and Find Full Text PDF
Article Synopsis
  • Immune checkpoint inhibitors (ICIs) have improved melanoma treatment, but finding effective drug combos with minimal side effects is essential.
  • A phase 1b study tested selinexor combined with pembrolizumab on 25 patients with advanced non-uveal melanoma, revealing high rates of adverse effects but most were manageable.
  • The results showed a 70% objective response rate in treatment-naïve patients, significantly better than the 7% response in those who had prior anti-PD-1 therapy, indicating promising antitumor activity.
View Article and Find Full Text PDF

Heart failure is a leading cause of death worldwide, and even with current treatments, the 5-year transplant-free survival rate is only ~50-70%. As such, there is a need to develop new treatments for patients that improve survival and quality of life. Recently, there have been efforts to develop small molecules for heart failure that directly target components of the sarcomere, including cardiac myosin.

View Article and Find Full Text PDF
Article Synopsis
  • - BMS-986156 is a new treatment that enhances T-cell activation and, when combined with other therapies like ipilimumab and nivolumab, shows promise in controlling tumors in advanced solid cancers.
  • - The study enrolled 50 patients with stage IV cancers resistant to standard treatments, dividing them into three groups receiving varying combinations of BMS-986156, ipilimumab, or nivolumab, with and without stereotactic ablative radiotherapy (SABR).
  • - Results indicated that the combination therapies were generally well tolerated, though 44% of patients experienced treatment-related adverse events, with 12% having more severe events, such as increased liver enzyme levels.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!